Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01736059 · ClinicalTrials.gov registry record · Phase 1

Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

A Phase 1 study of Diabetic Retinopathy and Retinitis Pigmentosa, sponsored by University of California, Davis.

Active
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT01736059: Active Phase 1 study of Diabetic Retinopathy and Retinitis Pigmentosa, sponsored by University of California, Davis.

NCT01736059 is a Phase 1 study of Diabetic Retinopathy and Retinitis Pigmentosa that is active but no longer recruiting, run by University of California, Davis. The registered enrollment target is 15 participants, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01736059, a Phase 1 study of Diabetic Retinopathy and Retinitis Pigmentosa, is active but no longer recruiting, sponsored by University of California, Davis.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.

Primary Outcome

As evident on eye examination by severe decrease in vision and/or adverse effect requiring major treatment intervention directly attributable to study treatment.

Interventions

  • DRUG CD34+ bone marrow stem cells intravitreal

Study Locations (1)

California

  • University of California Davis - Sacramento

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2012-07
Est. Completion 2026-10
Phase Phase 1
University of California, Davis

657 total trials

What the registry record for NCT01736059 still lists

NCT01736059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (99% lower).

The record links to 5 conditions, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which CD34+ bone marrow stem cells intravitreal is the first listed.

NCT01736059 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01736059 about?

NCT01736059 is a clinical study titled "Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy". This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.

What is the current status of trial NCT01736059?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2012-07. Estimated completion is 2026-10.

What conditions does trial NCT01736059 study?

This clinical trial studies the following conditions: Diabetic Retinopathy, Retinitis Pigmentosa, Non-exudative Age-related Macular Degeneration, Retina Vein Occlusion, Hereditary Macular Degeneration.

What interventions are being tested in trial NCT01736059?

The interventions under investigation include: CD34+ bone marrow stem cells intravitreal (DRUG).

Who is sponsoring clinical trial NCT01736059?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01736059 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Retinopathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01736059's enrollment target sits among peer trials

15 53rd of 57 higher than 5 of 57 other Diabetic Retinopathy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01736059, the US trial registry maintained by the National Library of Medicine. NCT01736059 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.